Back to Agenda
[V5-S5] Responses Against the Global Threat of Antimicrobial Resistance
Session Chair(s)
Junko Sato, PhD
Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
By 2050, the global mortality attributable to antimicrobial resistance (AMR) is estimated to be 10 million, exceeding the mortality attributable to cancer if no actions are taken. In response to this issue, the Japanese government has proposed the “National Action Plan on AMR”. Various measurements against AMR have been considered by industry, government and academia, in areas ranging from drug discovery to the development of new antimicrobials, surveillance and appropriate use of antimicrobials. Focusing on the clinical research and development to tackle AMR, the current issues of the industry, government and academia and future steps for collaboration to efficiently and rapidly develop antimicrobials will be discussed in this session from local and global perspectives.
Speaker(s)
Therapeutic Drug for AMR Infections: from Regulatory Standpoint
Wataru Asakura, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Office Director, Office of New Drug IV
Development Issues of Drugs for AMR Infections
Mari Ariyasu
Shionogi & Co., Ltd., Japan
Head of Project Management 4, Senior Director
Can We Develop Antimicrobials for AMR Infections ? We Can Do It !
Satoshi Iwata, MD, PhD
National Cancer Center Hospital, Japan
Director, Department of Infectious Diseases,
Have an account?